IBRX Surges 30% as Reddit Buzz Builds Around Short Squeeze Potential

IBRX surged 30.80% on January 15 after reporting preliminary 2025 results showing Anktiva revenue jumped 700% to $113 million.
Reddit discussion in r/Shortsqueeze and r/pennystocks focused on high short interest (~37-40% of float), 8-10 days to cover, and multiple catalysts including FDA approvals and upcoming data.
The stock has risen 67% over the past week, driven by news of Saudi FDA approval for its ANKTIVA + checkpoint inhibitor and positive lung cancer data.

ImmunityBio (

$IBRX) surged 30.80% on January 15, 2026, after reporting preliminary 2025 results showing Anktiva revenue jumped 700% to $113 million from $15 million in 2024. The bladder cancer therapy also demonstrated positive data for non-small cell lung cancer expansion and received approval in Saudi Arabia, driving investor optimism despite the stock's long-term decline since its 2015 IPO.

Reddit Discussion Highlights Short Squeeze Potential

Reddit discussion across multiple subreddits focused on

$IBRX's short squeeze potential, with high short interest and multiple catalysts driving the narrative. In r/Shortsqueeze, a post with 269 upvotes and 188 comments noted that "with $4.50 being the forced covering zone short squeeze price point, 8 days to cover, and 37% short interest the sky is the limit." Another post in the same subreddit with 112 upvotes highlighted Fintel reporting short interest around 37% with 8 days to cover, and pointed to upcoming announcements from Dr. Pat Soon-Shiong.

In r/pennystocks, a post with 68 upvotes and 73 comments described

$IBRX as "the perfect setup for an insane short squeeze," citing short interest of ~40% of float, ~10 days to cover, and rising cost to borrow. The post also noted that "the Chairman promised multiple press releases in a row" and listed upcoming catalysts including positive lung cancer data on Jan 13 and Saudi FDA approval on Jan 14.

A r/wallstreetbets post with 22 upvotes detailed a long-term holder's experience, noting the stock "is up 29% today and 67% over the past week" and highlighting "incredibly promising news coming out currently."

Catalysts and Sentiment

The Reddit discussion centers on several key catalysts: the Saudi FDA approval for IBRX's ANKTIVA + checkpoint inhibitor, which is "the first approved chemotherapy-free immunotherapy that activates both natural killer cells and killer T cells," heralding what some call "immunotherapy 2.0." Additional catalysts include upcoming data for glioblastoma and CAR-NK, as well as positive non-small cell lung cancer data.

Sentiment across the ticker-specific Reddit posts is strongly positive, with an average sentiment score of 0.77 on a scale from -1 to 1. The r/Shortsqueeze subreddit showed an average sentiment of 0.77, while r/pennystocks had an average of 0.65, reflecting broad bullishness across the discussion.

IBRX

Subscribe to Tendie.bot for more market recaps.